… Selexipag is a prostacyclin … in the metabolism of selexipag and its active metabolite,
ACT-333679. This study evaluated the interaction of selexipag and clopidogrel, a CYP2C8 inhibitor. …

… the active metabolite ACT-333679 is catalysed by carboxylesterases, while the oxidation and
dealkylation reactions are metabolized by CYP2C8 … The potential of selexipag to inhibit or …

… on the pharmacokinetics of selexipag and its active metabolite and suggested that … the effect
of clopidogrel, an inhibitor of CYP2C8, on the PK of selexipag and ACT-33367 in Japanese …

… (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT-333679.
The … of selexipag with gemfibrozil, a strong CYP2C8 inhibitor, and rifampicin, an inducer of …

… CYP2C8, selexipag is a strong inhibitor of CYP2C8 at the same time. Meanwhile, CYP2C8
is an extent inhibited … primarily by CYP2C8 and may compete with selexipag for CYP2C8. In …

… that CYP2C8 and CYP3A4 are involved in the metabolism of … of selexipag and its metabolites
in animals and humans 24, subjects administered selexipag concomitantly with inhibitors …

… pathway bypass significant liver metabolism and avoid drug interactions, selexipag and
oral treprostinil may exhibit interactions with CYP2C8 inhibitors such as gemfibrozil and …

… Selexipag and its active metabolite do not activate or inhibit the P450 enzyme system, but
concomitant use of CYP2C8 inhibitors (eg gemfibrozil) with selexipag … high levels of selexipag […

… PGI 2 and its analogs act as potent vasodilators and inhibit platelet aggregation via the PGI
… and MRE-269 are converted into several metabolites by recombinant CYP2C8 and CYP3A4, …

… study between a strong CYP2C8 inhibitor gemfibrozil and selexipag with ACT-333679 has …
for the simultaneous detection of selexipag as well as its metabolite ACT-333679 in biological …